Purpose: Carcinoid heart disease (CHD) with severe valve destruction represents the major cause of high morbidity and mortality in patients with carcinoid syndrome. In this paper, we present a novel interventional treatment approach and report the first clinical result achieved in a patient with extensive CHD. Methods and Results: A woman with an ileal neuroendocrine tumour (G2, Ki67: 5%) presented with severe CHD (NYHA IV) affecting both the pulmonary and the tricuspid valve. First, a balloon-expandable 23-mm Edwards SAPIEN™ was successfully implanted percutaneously into the pulmonary valve. Since no catheter-based techniques were available for the replacement of the native tricuspid valve, we implanted an Edwards SAPIEN 26-mm valve into the vena cava inferior between the right atrium and the ostium of the hepatic veins to reduce abdominal congestion. The implantation was technically successful and completely prevented regurgitation into the vena cava inferior and abdominal veins. After this procedure, the patient's clinical condition improved significantly, and she achieved near-normal exercise tolerance (VO2 max: 24.4 ml O2/kg/min, NYHA II). Conclusion: We demonstrated that percutaneous valve implantation may offer a novel, minimally invasive option in high-risk patients with severe CHD.

Keywords:
Right heart failure, Ileal neuroendocrine tumour, Carcinoid heart disease
1.
Møller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM: Valvular heart disease: prognosis of carcinoid heart disease - analysis of 200 cases over two decades. Circulation 2005;112:3320-3327.
2.
Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, Fossmark R, Bakke I, Szversen U, Waldum H: Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-1522.
3.
Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196.
4.
Laule M, Stangl V, Sanad W, Lembcke A, Baumann G, Stangl K: Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience. J Am Coll Cardiol 2013;61:1929-1931.
5.
Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK: Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410-416.
6.
Lurz P, Bonhoeffer P, Taylor AM: Percutaneous pulmonary valve implantation: an update. Expert Rev Cardiovasc Ther 2009;7:823-833.
7.
Jalal Z, Thambo JB, Boudjemline Y: The future of transcatheter pulmonary valvulation. Arch Cardiovasc Dis 2014;107:635-642.
8.
Mabvuure N, Cumberworth A, Hindocha S: In patients with carcinoid syndrome undergoing valve replacement: will a biological valve have acceptable durability? Interact Cardiovasc Thorac Surg 2012;15:467-471.
9.
Palaniswamy C, Frishman WH, Aronow WS: Carcinoid heart disease. Cardiol Rev 2012;20:167-176.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.